Arcus Biosciences RCUS Total Liabilities & Equity
Total Liabilities & Equity at other companies
Other financials
Where this comes from
Reported directly by Arcus Biosciences in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.
The official record: Arcus Biosciences’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Arcus Biosciences's total liabilities & equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Arcus Biosciences's total liabilities & equity?
- Arcus Biosciences (RCUS) reported total liabilities & equity of $997M in Q1 2026.
- How has Arcus Biosciences's total liabilities & equity changed year-over-year?
- Arcus Biosciences's total liabilities & equity decreased by 13.8% year-over-year, from $1.16B to $997M.
- What is the long-term trend for Arcus Biosciences's total liabilities & equity?
- Over 5 years (2020 to 2025), Arcus Biosciences's total liabilities & equity has grown at a 8.1% compound annual growth rate (CAGR), from $772.29M to $1.14B.
- What does total liabilities & equity mean?
- Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.